Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

James Reeves

Medical Oncology Fort Myers, FL Medical Doctor

NPI 1447233986 CMS profile 20180

8260 Gladiolus Dr, Fort Myers, FL 33908

Open in the dashboard

General payments

$40,094

203 records reported · program years 2019–2024

Research payments

$19,261

Paid to them · 7 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,058,539 paid to institutions, not to them · program years 2019–2025

Through program year 2024, James Reeves of Fort Myers, FL is reported in the CMS Open Payments database as having received $40,094 across 203 general payments and $19,261 in research payments paid to them. Separately, studies naming them as principal investigator received $7,058,539 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $34 2
2022 General $1,801 21
2021 General $1,573 17
2021 Research $813 1
2020 General $6,514 71
2020 Research $2,579 2
2019 General $30,172 92
2019 Research $15,870 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Reeves
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to James Reeves were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year James Reeves Medical Oncology median Middle half National median
2019 $30,172 $968 $140–$6,658 $163
2020 $6,514 $747 $102–$5,891 $114
2021 $1,573 $430 $50–$4,098 $132
2022 $1,801 $812 $127–$4,907 $149
2023 $0 $957 $144–$5,248 $160
2024 $34 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Eisai Inc. $18,100 22 payments
  2. Janssen Biotech, Inc. $12,512 16 payments
  3. AstraZeneca Pharmaceuticals LP $870 10 payments
  4. E.R. Squibb & Sons, L.L.C. $837 9 payments
  5. Genzyme Corporation $788 13 payments
  6. Exelixis Inc. $567 7 payments
  7. Celgene Corporation $476 8 payments
  8. Daiichi Sankyo Inc. $459 8 payments
  9. W. L. Gore & Associates, Inc. $436 3 payments
  10. Merck Sharp & Dohme Corporation $410 11 payments
  11. Other $4,639 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,280 14 payments
  2. Food and Beverage $9,028 175 payments
  3. Travel and Lodging $2,611 8 payments
  4. Education $806 4 payments
  5. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $248 1 payment
  6. Consulting Fee $121 1 payment
Products named General payments · program years 2019–2024
  1. Lenvima $18,100 22 payments
  2. ERLEADA $12,426 12 payments
  3. ENHERTU $444 5 payments
  4. GORE TAG Thoracic Endoprosthesis $436 3 payments
  5. CABOMETYX $432 6 payments
  6. FOUNDATIONONE CDX $354 3 payments
  7. FOUNDATIONONE $354 3 payments
  8. FOUNDATIONFOCUS $354 3 payments
  9. FOUNDATIONONE HEME $354 3 payments
  10. FOUNDATIONONE LIQUID $354 3 payments
  11. Other $7,687 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $17,222 2 payments
  2. F. Hoffmann-La Roche AG $1,569 2 payments
  3. Celgene Corporation $403 1 payment
  4. Takeda Pharmaceuticals U.S.A., Inc. $67 2 payments

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record